MANA and CSI Report Fipronil Manufacturing Error

Makhteshim Agan of North America (MANA) and Control Solutions Inc. (CSI) filed a notification in the United States District Court acknowledging that two lots of Taurus SC product were not formulated with fipronil technical material made in accordance with a process known as the “Currently Intended Process.”

Upon discovering the “one-time human error,” the companies audited all lots of the Taurus SC product and confirmed that, with the exception of the two lots from Colombia, the remainder were all manufactured according to the approved process.

Advertisement

The product of the two lots in question was formulated in the beginning of 2012 in a single run at Makhteshim Agan Group’s (MAI) subsidiary in Colombia, South America. The Colombian manufacturing facility inadvertently formulated the Taurus SC product with the incorrect fipronil technical material which was not intended to be used in products destined for the U.S. market.

Shaul Friedland, head of MAI’s Americas region said, “We acknowledge this instance of human error, which occurred due to a temporary relocation of Taurus SC production to Colombia, while our plant in Israel was dealing with a temporary manufacturing issue and prior to the start of CSI’s Texas production. We have already verified that neither CSI nor we have any stock of product from the two lots in question. We have also asked our distributors who may still have inventory of the two lots to immediately return that product to CSI.”

CSI’s plant in Texas began formulating Taurus SC as of July 2012, and all future production of fipronil material intended for the U.S. will be performed at either CSI’s plant or at MAI’s facility in Israel.